311 related articles for article (PubMed ID: 1329068)
1. Novel animal model for evaluating topical efficacy of antiviral agents: flux versus efficacy correlations in the acyclovir treatment of cutaneous herpes simplex virus type 1 (HSV-1) infections in hairless mice.
Lee PH; Su MH; Kern ER; Higuchi WI
Pharm Res; 1992 Aug; 9(8):979-89. PubMed ID: 1329068
[TBL] [Abstract][Full Text] [Related]
2. Influence of the treatment protocol upon the in vivo efficacy of cidofovir (HPMPC) and of acyclovir (ACV) formulations in topical treatment of cutaneous HSV-1 infection in hairless mice.
Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; DeClercq E; El-Shattawy HH
J Pharm Sci; 1999 May; 88(5):530-4. PubMed ID: 10229644
[TBL] [Abstract][Full Text] [Related]
3. Correlation of in vivo topical efficacies with in vitro predictions using acyclovir formulations in the treatment of cutaneous HSV-1 infections in hairless mice: an evaluation of the predictive value of the C* concept.
Patel PJ; Ghanem AH; Higuchi WI; Srinivasan V; Kern ER
Antiviral Res; 1996 Mar; 29(2-3):279-86. PubMed ID: 8739606
[TBL] [Abstract][Full Text] [Related]
4. Effect of Azone upon the in vivo antiviral efficacy of cidofovir or acyclovir topical formulations in treatment/prevention of cutaneous HSV-1 infections and its correlation with skin target site free drug concentration in hairless mice.
Afouna MI; Fincher TK; Zaghloul AA; Reddy IK
Int J Pharm; 2003 Mar; 253(1-2):159-68. PubMed ID: 12593946
[TBL] [Abstract][Full Text] [Related]
5. Estimation of skin target site acyclovir concentrations following controlled (trans)dermal drug delivery in topical and systemic treatment of cutaneous HSV-1 infections in hairless mice.
Imanidis G; Song WQ; Lee PH; Su MH; Kern ER; Higuchi WI
Pharm Res; 1994 Jul; 11(7):1035-41. PubMed ID: 7937545
[TBL] [Abstract][Full Text] [Related]
6. Relationship of skin target site free drug concentration (C*) to the in vivo efficacy: an extensive evaluation of the predictive value of the C* concept using acyclovir as a model drug.
Mehta SC; Afouna MI; Ghanem AH; Higuchi WI; Kern ER
J Pharm Sci; 1997 Jul; 86(7):797-801. PubMed ID: 9232519
[TBL] [Abstract][Full Text] [Related]
7. Synergistic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash in mice.
Lobe DC; Spector T; Ellis MN
Antiviral Res; 1991 Feb; 15(2):87-100. PubMed ID: 1650166
[TBL] [Abstract][Full Text] [Related]
8. Preclinical assessment of topical treatments of herpes simplex virus infection: 5% (E)-5-(2-bromovinyl)-2'-deoxyuridine cream.
Freeman DJ; Sacks SL; De Clercq E; Spruance SL
Antiviral Res; 1985 Jun; 5(3):169-77. PubMed ID: 2992371
[TBL] [Abstract][Full Text] [Related]
9. Synergistic therapy by acyclovir and A1110U for mice orofacially infected with herpes simplex viruses.
Ellis MN; Lobe DC; Spector T
Antimicrob Agents Chemother; 1989 Oct; 33(10):1691-6. PubMed ID: 2556074
[TBL] [Abstract][Full Text] [Related]
10. Penetration of guinea pig skin by acyclovir in different vehicles and correlation with the efficacy of topical therapy of experimental cutaneous herpes simplex virus infection.
Spruance SL; McKeough MB; Cardinal JR
Antimicrob Agents Chemother; 1984 Jan; 25(1):10-5. PubMed ID: 6703671
[TBL] [Abstract][Full Text] [Related]
11. Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.
Spector T; Lobe DC; Ellis MN; Blumenkopf TA; Szczech GM
Antimicrob Agents Chemother; 1992 May; 36(5):934-7. PubMed ID: 1324641
[TBL] [Abstract][Full Text] [Related]
12. Assessment of correlation between skin target site free drug concentration and the in vivo topical antiviral efficacy in hairless mice for (E)-5-(2-bromovinyl)-2'-deoxyuridine and acyclovir formulations.
Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; De Clercq E; El-Shattawy HH
J Pharm Sci; 1998 Aug; 87(8):917-21. PubMed ID: 9687333
[TBL] [Abstract][Full Text] [Related]
13. Acyclovir treatment of experimental genital herpes simplex virus infections. I. Topical therapy of type 2 and type 1 infections of mice.
Kern ER; Richards JT; Overall JC; Glasgow LA
Antiviral Res; 1983 Nov; 3(4):253-67. PubMed ID: 6320718
[TBL] [Abstract][Full Text] [Related]
14. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.
Duan J; Liuzzi M; Paris W; Lambert M; Lawetz C; Moss N; Jaramillo J; Gauthier J; Déziel R; Cordingley MG
Antimicrob Agents Chemother; 1998 Jul; 42(7):1629-35. PubMed ID: 9660995
[TBL] [Abstract][Full Text] [Related]
15. Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease.
Kristofferson A; Ericson AC; Sohl-Akerlund A; Datema R
J Gen Virol; 1988 Jun; 69 ( Pt 6)():1157-66. PubMed ID: 2838569
[TBL] [Abstract][Full Text] [Related]
16. Comparison of topically applied 5-ethyl-2'-deoxyuridine and acyclovir in the treatment of cutaneous herpes simplex virus infection in guinea pigs.
Spruance SL; Freeman DJ; Sheth NV
Antimicrob Agents Chemother; 1985 Jul; 28(1):103-6. PubMed ID: 4037770
[TBL] [Abstract][Full Text] [Related]
17. Effects of 2,2'-O-cyclocytidine and acyclovir on latent herpes simplex virus in trigeminal ganglia of mice.
Liu WG; Chen ZJ; Song JZ; Ma ZX
Antimicrob Agents Chemother; 1986 Feb; 29(2):278-80. PubMed ID: 2424367
[TBL] [Abstract][Full Text] [Related]
18. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell transplantation.
Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Transpl Infect Dis; 2013 Oct; 15(5):457-65. PubMed ID: 23895431
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet.
Reefschläger J; Wutzler P; Thiel KD; Herrmann G
Pharm Res; 1987 Jun; 4(3):200-6. PubMed ID: 2855541
[TBL] [Abstract][Full Text] [Related]
20. Cutaneously applied acyclovir acts systemically in the treatment of herpetic infection in the hairless mouse.
Bolger GT; Allen T; Garneau M; Lapeyre N; Liard F; Jaramillo J
Antiviral Res; 1997 Aug; 35(3):157-65. PubMed ID: 9298755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
